Goldman Sachs Group Inc. grew its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 17.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 134,043 shares of the biopharmaceutical company’s stock after buying an additional 20,379 shares during the quarter. Goldman Sachs Group Inc. owned 0.13% of Lexicon Pharmaceuticals worth $2,205,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at about $182,000. First Mercantile Trust Co. grew its stake in shares of Lexicon Pharmaceuticals by 11.2% during the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the last quarter. Cim Investment Mangement Inc. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at about $262,000. Pacad Investment Ltd. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at about $265,000. Finally, Legal & General Group Plc grew its stake in shares of Lexicon Pharmaceuticals by 2.6% during the second quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 465 shares during the last quarter.
In related news, insider Lonnel Coats bought 30,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were acquired at an average cost of $12.54 per share, for a total transaction of $376,200.00. The purchase was disclosed in a filing with the SEC, which is available through this link. 5.77% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Group Inc. Buys 20,379 Shares of Lexicon Pharmaceuticals, Inc. (LXRX)” was published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/31/goldman-sachs-group-inc-buys-20379-shares-of-lexicon-pharmaceuticals-inc-lxrx.html.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) opened at 10.20 on Tuesday. The company has a 50 day moving average price of $11.90 and a 200 day moving average price of $14.59. Lexicon Pharmaceuticals, Inc. has a 1-year low of $10.02 and a 1-year high of $18.00. The company’s market capitalization is $1.08 billion.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company’s revenue for the quarter was down 40.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.37) EPS. Equities analysts predict that Lexicon Pharmaceuticals, Inc. will post ($1.47) EPS for the current fiscal year.
A number of research analysts have recently issued reports on the company. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Wedbush reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average target price of $28.75.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
What are top analysts saying about Lexicon Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lexicon Pharmaceuticals Inc. and related companies.